Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB) is set to hold a conference call on November 5, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results and operational highlights. The call will be accessible via phone and an archived webcast will be available on the company’s website. Selecta is focused on its ImmTOR™ platform for developing therapies to mitigate immune responses, with significant programs in the pipeline, including a clinical trial for treating a rare metabolic disorder in early 2021. More details can be found at their website.

Positive

• Selecta's ImmTOR™ platform aims to improve the efficacy of biologic therapies.
• The company is entering clinical trials for a treatment of methylmalonic acidemia in early 2021.
• Selecta has licensed its SEL-212 product candidate for chronic refractory gout.

Negative

• None.

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on November 5, 2020 at 8:30 a.m. ET to discuss its financial results for the third quarter and recent operational highlights.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10138608. Investors and the public can access the live and archived webcast of this call via the Investors & Media section of the company’s website, www.selectabio.com. 

About Selecta Biosciences, Inc. 
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com 

For Media: 
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com 

FAQ

What is the date and time of the upcoming conference call for Selecta Biosciences?

The conference call is scheduled for November 5, 2020, at 8:30 a.m. ET.

What will Selecta Biosciences discuss during the conference call?

They will discuss their third-quarter financial results and recent operational highlights.

What is Selecta Biosciences focused on developing?

Selecta is focused on its ImmTOR™ platform aimed at developing therapies to mitigate unwanted immune responses.

When is Selecta's clinical trial for methylmalonic acidemia expected to start?

The clinical trial for treating methylmalonic acidemia is expected to start in early 2021.

What product candidate has Selecta recently licensed?

Selecta has licensed its Phase 3 product candidate, SEL-212, for chronic refractory gout.